1. Dixon T. Anxiety Disorders: Mental Illness Or Normal?: Help-For; 2020.
2. Adams D, Malone S. The impact of anxiety on decision making in individuals with intellectual and developmental disabilities or a diagnosis on the autism spectrum. Decision making by individuals with intellectual and developmental disabilities: Integrating research into practice: Springer; 2021. p. 173-96. [
DOI:10.1007/978-3-030-74675-9_8]
3. Tongta S, Daendee S, Kalandakanond-Thongsong S. Anxiety-like behavior and GABAergic system in ovariectomized rats exposed to chronic mild stress. Physiol Behav. 2023;258:114014. [
DOI:10.1016/j.physbeh.2022.114014] [
PMID]
4. Kundakovic M, Rocks D. Sex hormone fluctuation and increased female risk for depression and anxiety disorders: From clinical evidence to molecular mechanisms. Front Neuroendocrinol. 2022;66:101010. [
DOI:10.1016/j.yfrne.2022.101010] [
PMID] [
PMCID]
5. Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020;25(7):1270-6. [
DOI:10.1016/j.drudis.2020.05.001] [
PMID]
6. Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022;328(24):2431-45. [
DOI:10.1001/jama.2022.22744] [
PMID]
7. Hajebi A, Motevalian SA, Rahimi-Movaghar A, Sharifi V, Amin-Esmaeili M, Radgoodarzi R, et al. Major anxiety disorders in Iran: prevalence, sociodemographic correlates and service utilization. BMC Psychiatry. 2018;18(1):261. [
DOI:10.1186/s12888-018-1828-2] [
PMID] [
PMCID]
8. Tajik A, Nikfar S, Elyasi S, Rajabi O, Varmaghani M. Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran. Child Adolesc Psychiatry Ment Health. 2023;17(1):115. [
DOI:10.1186/s13034-023-00664-1] [
PMID] [
PMCID]
9. Horenstein A, Heimberg RG. Anxiety disorders and healthcare utilization: A systematic review. Clin Psychol Rev. 2020;81:101894. [
DOI:10.1016/j.cpr.2020.101894] [
PMID]
10. Benson C, Singer D, Carpinella CM, Shawi M, Alphs L. The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National Survey. Neuropsychiatr Dis Treat. 2021;17:111-23. [
DOI:10.2147/NDT.S229530] [
PMID] [
PMCID]
11. Gomez KU, McBride O, Roberts E, Angus C, Keyes K, Drummond C, et al. The clustering of physical health conditions and associations with co-occurring mental health problems and problematic alcohol use: a cross-sectional study. BMC Psychiatry. 2023;23(89):1-14. [
DOI:10.1186/s12888-023-04577-3] [
PMID] [
PMCID]
12. Rogers AH, Wieman ST, Baker AW. Anxiety comorbidities: mood disorders, substance use disorders, and chronic medical illness. Clinical handbook of anxiety disorders: From theory to practice2019. p. 77-103. [
DOI:10.1007/978-3-030-30687-8_5]
13. Hohls JK, König HH, Quirke E, Hajek A. Anxiety, Depression and Quality of Life-A Systematic Review of Evidence from Longitudinal Observational Studies. Int J Environ Res Public Health. 2021;18(22):12022. [
DOI:10.3390/ijerph182212022] [
PMID] [
PMCID]
14. Bartoli F, Carretta D, Carrà G. Comorbid anxiety and alcohol or substance use disorders: an overview. Textbook of Addiction Treatment: International Perspectives. 2020:1315-25. [
DOI:10.1007/978-3-030-36391-8_92]
15. Chandler TL, Dombrowski F. Mood and Anxiety Disorders. Co-occurring Mental Illness and Substance Use Disorders. 1 ed2022. p. 17-28. [
DOI:10.4324/9781003220916-3]
16. Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv Exp Med Biol. 2020;1191:347-65. [
DOI:10.1007/978-981-32-9705-0_19] [
PMID]
17. Zhang W, Yan Y, Wu Y, Yang H, Zhu P, Yan F, et al. Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis. Pharmacol Res. 2022;179:106204. [
DOI:10.1016/j.phrs.2022.106204] [
PMID]
18. Dave PH, Vishnupriya V, Gayathri R. Herbal remedies for anxiety and depression-a review. Res J Pharm Technol. 2016;9(8):1253-6. [
DOI:10.5958/0974-360X.2016.00237.7]
19. Mozaffarian V. Biodiversity of poisonous plants in Iran. Iran Nature. 2021;6(4):47-82.
20. EghbaliFeriz S, Taleghani A, Tayarani-Najaran Z. Central nervous system diseases and Scutellaria: a review of current mechanism studies. Biomed Pharmacother. 2018;102:185-95. [
DOI:10.1016/j.biopha.2018.03.021] [
PMID]
21. Zhang QW, Lin LG, Ye WC. Techniques for extraction and isolation of natural products: a comprehensive review. Chin Med. 2018;13:20. [
DOI:10.1186/s13020-018-0177-x] [
PMID] [
PMCID]
22. Gharari Z, Bagheri K, Sharafi A. Chemical Composition of Methanolic Extracts of Scutellaria orientalis L.: Digitoxin and Neocurdione Detection by Gas Chromatography/Mass Spectrometry. Pharm Biomed Res. 2022;8(1):53-6. [
DOI:10.18502/pbr.v8i1.9388]
23. Acikgoz B, Dalkiran B, Dayi A. An overview of the currency and usefulness of behavioral tests used from past to present to assess anxiety, social behavior and depression in rats and mice. Behav Processes. 2022;200:104670. [
DOI:10.1016/j.beproc.2022.104670] [
PMID]
24. Scult MA, Paulli AR, Mazure ES, Moffitt TE, Hariri AR, Strauman TJ. The association between cognitive function and subsequent depression: a systematic review and meta-analysis. Psychol Med. 2017;47(1):1-17. [
DOI:10.1017/S0033291716002075] [
PMID] [
PMCID]
25. Zehravi M, Karthika C, Azad AK, Ahmad Z, Khan FS, Rahman MS, et al. A Background Search on the Potential Role of Scutellaria and Its Essential Oils. Biomed Res Int. 2022;2022:7265445. [
DOI:10.1155/2022/7265445] [
PMID] [
PMCID]
26. Golmakani E, Mohammadi A, Sani TA, Kamali H. Phenolic and flavonoid content and antioxidants capacity of pressurized liquid extraction and perculation method from roots of Scutellaria pinnatifida A. Hamilt. subsp alpina (Bornm) Rech. f. J Supercrit Fluids. 2014;95:318-24. [
DOI:10.1016/j.supflu.2014.09.020]
27. Brock C. American skullcap (Scutellaria lateriflora L): a study of its effects on mood in healthy volunteers: University of Westminster; 2012. [
DOI:10.1186/ISRCTN48078312]
28. Sripathi R, Ravi S. Ethnopharmacology, phytoconstituents, essential oil composition and biological activities of the genus Scutellaria. J Pharm Sci & Res. 2017;9(3):275-8. [
DOI:10.25258/phyto.v9i5.8140]
29. Huen MS, Leung JW, Ng W, Lui WS, Chan MN, Wong JT, et al. 5,7-Dihydroxy-6-methoxyflavone, a benzodiazepine site ligand isolated from Scutellaria baicalensis Georgi, with selective antagonistic properties. Biochem Pharmacol. 2003;66(1):125-32. [
DOI:10.1016/S0006-2952(03)00233-8] [
PMID]
30. Merzoug S, Toumi ML, Boukhris N, Baudin B, Tahraoui A. Adriamycin-related anxiety-like behavior, brain oxidative stress and myelotoxicity in male Wistar rats. Pharmacol Biochem Behav. 2011;99(4):639-47. [
DOI:10.1016/j.pbb.2011.06.015] [
PMID]
31. Xu Y, Wang C, Klabnik JJ, O'Donnell JM. Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment. Curr Neuropharmacol. 2014;12(2):108-19. [
DOI:10.2174/1570159X11666131120231448] [
PMID] [
PMCID]
32. Saboura A, Ahmadi A, Zeinali A, Parsa M. Comparison Between the Contents of Phenolic and Flavonoid Compounds and Aerial Part Antioxidant Activity in Scutellaria pinnatifida in Two NorthIranian Populations. J Rafsanjan Univ Med Sci. 2014;13(3):249-66.
33. Delazar A, Nazemiyeh H, Afshar FH, Barghi N, Esnaashari S, Asgharian P. Chemical compositions and biological activities of Scutellaria pinnatifida A. Hamilt aerial parts. Res Pharm Sci. 2017;12(3):187-95. [
DOI:10.4103/1735-5362.207199] [
PMID] [
PMCID]